Management of chemotherapy-associated febrile neutropenia

British Journal of Cancer

Volumn 101, Issue , 2009, Pages S18-S22

  Cameron, D ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Chemotherapy; Febrile neutropenia; Local protocols; Management; Rapid referral

Indexed keywords

ANTINEOPLASTIC AGENTS; FEVER; HUMANS; NEUTROPENIA; PATIENT ADMISSION; REFERRAL AND CONSULTATION;

AMINOGLYCOSIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

BACTERIAL COLONIZATION; BREAST CANCER; CANCER CHEMOTHERAPY; DOCTOR PATIENT RELATION; FEBRILE NEUTROPENIA; HEALTH CARE PERSONNEL; HEALTH SERVICE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; LABORATORY TEST; MONOTHERAPY; NEUTROPENIA; PATIENT ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY;

EID: 70349218446     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605272     Document Type: Article

References (29)

1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinskil C, European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42: 2433–2453
2. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328–340
3. Boland A, Haycox A, Bagust A, Fitzsimmons L (2003) A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technol Assess 7: 1–99
4. Chamorey E, Magné N, Foa C, Otto J, Largillier R, Viot M, Benard-Thiery I, Thyss A (2004) Ceftriaxone monotherapy for the treatment of febrile neutropenia in patients with solid tumors: a prospective study of 100 episodes. Med Sci Monit 10: 119–125
5. Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J, Study Group (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17: 2341–2354
6. Cometta A, Glauser MP (1996) Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. J Chemother 8: 375–381
7. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, Hiemenz S, Hicks JE, Gill V, Steinberg SM, Pizzo PA (1999) A doubleblind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341: 305–311
8. Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142: 979–995
9. Gillis S, Dann EJ, Rund D (1996) Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Am J Hematol 51: 26–31
10. Hall JB, Schmidt GA, Wood LDH (2005) Principles of Critical Care 3rd edn, 737. Mcgraw Hill Text: Columbus
11. Head J, Archer C, Harper-Wynne C, Sinha R, Ring A, Banner R, Sutherland S, Johnston S (2008) Rates of neutrpaenic sepsis with the use of adjuvant FEC100-Docetaxel (FEC100-T) chemotherapy in high-risk node-positive patients with early breast cancer; a UK perspective. National Cancer Research Institute Cancer Conference; Abstract B64, http://www.ncri.org.uk/ncriconference/archive/2008/2008Abstracts.asp
12. Hoy CM (2009) Antimicrobial therapy for pyrexia in neutropenic patients. Doncaster and Bassetlaw Hospitals NHS Foundation Trust
13. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, CAlandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS (2002) 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34: 730–751
14. Karthaus M, Wolf HH, Kämpfe D, Egerer G, Ritter J, Peters G, Südhoff T, Franke A, Heil G, Kullmann KH, Jürgens H (1998) Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia. Chemotherapy 44: 343–354
15. Kelly S, Wheatley D (2009) Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. Br J Cancer 101(Suppl 1): S6–S10
16. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341: 312–318
17. Krell D, Jones AL (2009) Impact of effective prevention and management of febrile neutropenia. Br J Cancer 101(Suppl 1): S23–S26
18. Leonard RCF, Miles D, Thomas R, Nussey F, on behalf of the UK Breast Cancer Neutropenia Audit Group (2003) Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 89: 2062–2068
19. Lyman GH, Lyman CH, Agboola O, for the ANC Study Group (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10: 427–437
20. Malik I, Hussain M, Yousuf H (2001) Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. J Infect 42: 120–125
21. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA (1995) Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 98: 224 –231
22. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez- Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C, Breast Cancer International Research Group 001 Investigators (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302–2313
23. Meza L, Baselga J, Holmes FA, Liang B, Breddy J, for the Pegfilgrastim Study Group (2002) Incidence of febrile neutropenia (FN) is directly related to duration of sever neutropenia (DSN) after myelosuppressive chemotherapy. Proc Am Soc Clin Oncol 21: Abstract 2840
24. Moores KG (2007) Safe and effective outpatient treatment of adults with chemotherapy-induced neutropenic fever. Am J Health Syst Pharm 64: 717–722
25. National Chemotherapy Advisory Group (2009) Chemotherapy Services in England: Ensuring Quality and Safety. NCAG: London
26. National Confidential Enquiry into Patient Outcome and Death (2008) For Better, for Worse?. NCEPOD: London
27. North Wales Cancer Network (2007) Guidelines for the Use of Colony Stimulating Factor (G-CSF) in Adult Patients with Solid Tumours. NWCN: St Asaph
28. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24: 3187–3205
29. Ziglam HM, Gelly K, Olver W (2007) A survey of the management of neutropenic fever in oncology units in the UK. Int J Antimicrob Agents 29: 430–433